Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Identification of regulators of the myofibroblast phenotype of primary dermal fibroblasts from early diffuse systemic sclerosis patients.

Chadli L, Sotthewes B, Li K, Andersen SN, Cahir-McFarland E, Cheung M, Cullen P, Dorjée A, de Vries-Bouwstra JK, Huizinga TWJ, Fischer DF, DeGroot J, Viney JL, Zheng TS, Aarbiou J, Gardet A.

Sci Rep. 2019 Mar 14;9(1):4521. doi: 10.1038/s41598-019-41153-w.

2.

Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models.

Toledo-Sherman L, Breccia P, Cachope R, Bate JR, Angulo-Herrera I, Wishart G, Matthews KL, Martin SL, Cox HC, McAllister G, Penrose SD, Vater H, Esmieu W, Van de Poël A, Van de Bospoort R, Strijbosch A, Lamers M, Leonard P, Jarvis RE, Blackaby W, Barnes K, Eznarriaga M, Dowler S, Smith GD, Fischer DF, Lazari O, Yates D, Rose M, Jang SW, Muñoz-Sanjuan I, Dominguez C.

J Med Chem. 2019 Mar 28;62(6):2988-3008. doi: 10.1021/acs.jmedchem.8b01819. Epub 2019 Mar 19.

PMID:
30840447
3.

Assessment of p.Phe508del-CFTR functional restoration in pediatric primary cystic fibrosis airway epithelial cells.

Sutanto EN, Scaffidi A, Garratt LW, Looi K, Foo CJ, Tessari MA, Janssen RA, Fischer DF, Stick SM, Kicic A; AREST CF.

PLoS One. 2018 Jan 23;13(1):e0191618. doi: 10.1371/journal.pone.0191618. eCollection 2018.

4.

Quantification of huntingtin protein species in Huntington's disease patient leukocytes using optimised electrochemiluminescence immunoassays.

Hensman Moss DJ, Robertson N, Farmer R, Scahill RI, Haider S, Tessari MA, Flynn G, Fischer DF, Wild EJ, Macdonald D, Tabrizi SJ.

PLoS One. 2017 Dec 22;12(12):e0189891. doi: 10.1371/journal.pone.0189891. eCollection 2017.

5.

A small molecule mitigates hearing loss in a mouse model of Usher syndrome III.

Alagramam KN, Gopal SR, Geng R, Chen DH, Nemet I, Lee R, Tian G, Miyagi M, Malagu KF, Lock CJ, Esmieu WR, Owens AP, Lindsay NA, Ouwehand K, Albertus F, Fischer DF, Bürli RW, MacLeod AM, Harte WE, Palczewski K, Imanishi Y.

Nat Chem Biol. 2016 Jun;12(6):444-51. doi: 10.1038/nchembio.2069. Epub 2016 Apr 25.

6.

Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease.

Lu XH, Mattis VB, Wang N, Al-Ramahi I, van den Berg N, Fratantoni SA, Waldvogel H, Greiner E, Osmand A, Elzein K, Xiao J, Dijkstra S, de Pril R, Vinters HV, Faull R, Signer E, Kwak S, Marugan JJ, Botas J, Fischer DF, Svendsen CN, Munoz-Sanjuan I, Yang XW.

Sci Transl Med. 2014 Dec 24;6(268):268ra178. doi: 10.1126/scitranslmed.3010523.

PMID:
25540325
7.

Quantification assays for total and polyglutamine-expanded huntingtin proteins.

Macdonald D, Tessari MA, Boogaard I, Smith M, Pulli K, Szynol A, Albertus F, Lamers MB, Dijkstra S, Kordt D, Reindl W, Herrmann F, McAllister G, Fischer DF, Munoz-Sanjuan I.

PLoS One. 2014 May 9;9(5):e96854. doi: 10.1371/journal.pone.0096854. eCollection 2014.

8.

A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease.

Todd D, Gowers I, Dowler SJ, Wall MD, McAllister G, Fischer DF, Dijkstra S, Fratantoni SA, van de Bospoort R, Veenman-Koepke J, Flynn G, Arjomand J, Dominguez C, Munoz-Sanjuan I, Wityak J, Bard JA.

PLoS One. 2014 Feb 4;9(2):e87923. doi: 10.1371/journal.pone.0087923. eCollection 2014.

9.

Synthetic studies on pseudo-dimeric Lycopodium alkaloids: total synthesis of complanadine B.

Newton JN, Fischer DF, Sarpong R.

Angew Chem Int Ed Engl. 2013 Feb 4;52(6):1726-30. doi: 10.1002/anie.201208571. Epub 2013 Jan 10. No abstract available.

10.

Mutant ubiquitin decreases amyloid β plaque formation in a transgenic mouse model of Alzheimer's disease.

van Tijn P, Dennissen FJ, Gentier RJ, Hobo B, Hermes D, Steinbusch HW, Van Leeuwen FW, Fischer DF.

Neurochem Int. 2012 Oct;61(5):739-48. doi: 10.1016/j.neuint.2012.07.007. Epub 2012 Jul 14.

PMID:
22797007
11.

Alzheimer-associated mutant ubiquitin impairs spatial reference memory.

van Tijn P, Hobo B, Verhage MC, Oitzl MS, van Leeuwen FW, Fischer DF.

Physiol Behav. 2011 Feb 1;102(2):193-200. doi: 10.1016/j.physbeh.2010.11.001. Epub 2010 Nov 6.

PMID:
21059367
12.

Histological and functional benefit following transplantation of motor neuron progenitors to the injured rat spinal cord.

Rossi SL, Nistor G, Wyatt T, Yin HZ, Poole AJ, Weiss JH, Gardener MJ, Dijkstra S, Fischer DF, Keirstead HS.

PLoS One. 2010 Jul 29;5(7):e11852. doi: 10.1371/journal.pone.0011852.

13.

Total synthesis of (+)-complanadine A using an iridium-catalyzed pyridine C-H functionalization.

Fischer DF, Sarpong R.

J Am Chem Soc. 2010 May 5;132(17):5926-7. doi: 10.1021/ja101893b.

14.

Low levels of mutant ubiquitin are degraded by the proteasome in vivo.

van Tijn P, Verhage MC, Hobo B, van Leeuwen FW, Fischer DF.

J Neurosci Res. 2010 Aug 15;88(11):2325-37. doi: 10.1002/jnr.22396.

PMID:
20336771
15.

Modest proteasomal inhibition by aberrant ubiquitin exacerbates aggregate formation in a Huntington disease mouse model.

de Pril R, Hobo B, van Tijn P, Roos RA, van Leeuwen FW, Fischer DF.

Mol Cell Neurosci. 2010 Mar;43(3):281-6. doi: 10.1016/j.mcn.2009.12.001. Epub 2009 Dec 18.

PMID:
20005957
16.

The asymmetric aza-Claisen rearrangement: development of widely applicable pentaphenylferrocenyl palladacycle catalysts.

Fischer DF, Barakat A, Xin ZQ, Weiss ME, Peters R.

Chemistry. 2009 Sep 7;15(35):8722-41. doi: 10.1002/chem.200900712.

PMID:
19691065
17.

The alpha7 nicotinic acetylcholine receptor on fibroblast-like synoviocytes and in synovial tissue from rheumatoid arthritis patients: a possible role for a key neurotransmitter in synovial inflammation.

van Maanen MA, Stoof SP, van der Zanden EP, de Jonge WJ, Janssen RA, Fischer DF, Vandeghinste N, Brys R, Vervoordeldonk MJ, Tak PP.

Arthritis Rheum. 2009 May;60(5):1272-81. doi: 10.1002/art.24470.

18.

Intermediate filament transcription in astrocytes is repressed by proteasome inhibition.

Middeldorp J, Kamphuis W, Sluijs JA, Achoui D, Leenaars CH, Feenstra MG, van Tijn P, Fischer DF, Berkers C, Ovaa H, Quinlan RA, Hol EM.

FASEB J. 2009 Aug;23(8):2710-26. doi: 10.1096/fj.08-127696. Epub 2009 Mar 30.

19.

The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons.

Thathiah A, Spittaels K, Hoffmann M, Staes M, Cohen A, Horré K, Vanbrabant M, Coun F, Baekelandt V, Delacourte A, Fischer DF, Pollet D, De Strooper B, Merchiers P.

Science. 2009 Feb 13;323(5916):946-51. doi: 10.1126/science.1160649.

20.

Long-term proteasome dysfunction in the mouse brain by expression of aberrant ubiquitin.

Fischer DF, van Dijk R, van Tijn P, Hobo B, Verhage MC, van der Schors RC, Li KW, van Minnen J, Hol EM, van Leeuwen FW.

Neurobiol Aging. 2009 Jun;30(6):847-63. doi: 10.1016/j.neurobiolaging.2008.06.009. Epub 2008 Aug 28.

PMID:
18760506
21.

An estrogenic effect of 5alpha-androstane-3beta, 17beta-diol on the behavioral response to stress and on CRH regulation.

Huang Q, Zhu H, Fischer DF, Zhou JN.

Neuropharmacology. 2008 Jun;54(8):1233-8. doi: 10.1016/j.neuropharm.2008.03.016. Epub 2008 Apr 4.

PMID:
18457850
22.

The neuronal ubiquitin-proteasome system: murine models and their neurological phenotype.

van Tijn P, Hol EM, van Leeuwen FW, Fischer DF.

Prog Neurobiol. 2008 Jun;85(2):176-93. doi: 10.1016/j.pneurobio.2008.03.001. Epub 2008 Mar 18. Review.

PMID:
18448229
23.

Proteasome subunit proteins and neuropathology in tauopathies and synucleinopathies: Consequences for proteomic analyses.

Zouambia M, Fischer DF, Hobo B, De Vos RA, Hol EM, Varndell IM, Sheppard PW, Van Leeuwen FW.

Proteomics. 2008 Mar;8(6):1221-36. doi: 10.1002/pmic.200700679.

PMID:
18283660
24.

Asymmetric formation of allylic amines with N-substituted quaternary stereocenters by Pd(II)-catalyzed aza-Claisen rearrangements.

Fischer DF, Xin ZQ, Peters R.

Angew Chem Int Ed Engl. 2007;46(40):7704-7. No abstract available.

PMID:
17722138
25.
26.

Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease.

van Tijn P, de Vrij FM, Schuurman KG, Dantuma NP, Fischer DF, van Leeuwen FW, Hol EM.

J Cell Sci. 2007 May 1;120(Pt 9):1615-23. Epub 2007 Apr 3.

27.

Identification of regulatory elements by gene family footprinting and in vivo analysis.

Fischer DF, Backendorf C.

Adv Biochem Eng Biotechnol. 2007;104:37-64. Review.

PMID:
17290818
28.

Ubiquitin-conjugating enzyme E2-25K increases aggregate formation and cell death in polyglutamine diseases.

de Pril R, Fischer DF, Roos RA, van Leeuwen FW.

Mol Cell Neurosci. 2007 Jan;34(1):10-9. Epub 2006 Nov 7.

PMID:
17092742
29.

Estrogen receptor alpha and its splice variants in the hippocampus in aging and Alzheimer's disease.

Ishunina TA, Fischer DF, Swaab DF.

Neurobiol Aging. 2007 Nov;28(11):1670-81. Epub 2006 Sep 27.

PMID:
17010478
30.

Ubiquitin proteasome system as a pharmacological target in neurodegeneration.

Hol EM, Fischer DF, Ovaa H, Scheper W.

Expert Rev Neurother. 2006 Sep;6(9):1337-47. Review.

PMID:
17009921
31.

Frameshift proteins in Alzheimer's disease and in other conformational disorders: time for the ubiquitin-proteasome system.

van Leeuwen FW, Hol EM, Fischer DF.

J Alzheimers Dis. 2006;9(3 Suppl):319-25. Review.

PMID:
16914870
32.

Total syntheses of the antibacterial natural product abyssomicin C.

Peters R, Fischer DF.

Angew Chem Int Ed Engl. 2006 Sep 4;45(35):5736-9. No abstract available.

PMID:
16906621
33.

Practical, highly active, and enantioselective ferrocenyl-imidazoline palladacycle catalysts (FIPs) for the aza-Claisen rearrangement of N-para-methoxyphenyl trifluoroacetimidates.

Weiss ME, Fischer DF, Xin ZQ, Jautze S, Schweizer WB, Peters R.

Angew Chem Int Ed Engl. 2006 Aug 25;45(34):5694-8. No abstract available.

PMID:
16858701
34.

Pineal clock gene oscillation is disturbed in Alzheimer's disease, due to functional disconnection from the "master clock".

Wu YH, Fischer DF, Kalsbeek A, Garidou-Boof ML, van der Vliet J, van Heijningen C, Liu RY, Zhou JN, Swaab DF.

FASEB J. 2006 Sep;20(11):1874-6. Epub 2006 Jul 3.

PMID:
16818472
35.

A direct androgenic involvement in the expression of human corticotropin-releasing hormone.

Bao AM, Fischer DF, Wu YH, Hol EM, Balesar R, Unmehopa UA, Zhou JN, Swaab DF.

Mol Psychiatry. 2006 Jun;11(6):567-76.

PMID:
16446741
36.

Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies.

van Leeuwen FW, van Tijn P, Sonnemans MA, Hobo B, Mann DM, Van Broeckhoven C, Kumar-Singh S, Cras P, Leuba G, Savioz A, Maat-Schieman ML, Yamaguchi H, Kros JM, Kamphorst W, Hol EM, de Vos RA, Fischer DF.

Neurology. 2006 Jan 24;66(2 Suppl 1):S86-92.

PMID:
16432153
37.

Conformational diseases: an umbrella for various neurological disorders with an impaired ubiquitin-proteasome system.

de Pril R, Fischer DF, van Leeuwen FW.

Neurobiol Aging. 2006 Apr;27(4):515-23. Epub 2005 Oct 13. Review.

PMID:
16226348
38.

Alzheimer-associated APP+1 transgenic mice: frameshift beta-amyloid precursor protein is secreted in cerebrospinal fluid without inducing neuropathology.

Fischer DF, Hol EM, Hobo B, van Leeuwen FW.

Neurobiol Aging. 2006 Oct;27(10):1445-50. Epub 2005 Oct 7.

PMID:
16214267
39.

The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1.

Hol EM, van Leeuwen FW, Fischer DF.

Trends Mol Med. 2005 Nov;11(11):488-95. Epub 2005 Oct 6. Review.

PMID:
16213790
41.

Activation of the Notch pathway in Down syndrome: cross-talk of Notch and APP.

Fischer DF, van Dijk R, Sluijs JA, Nair SM, Racchi M, Levelt CN, van Leeuwen FW, Hol EM.

FASEB J. 2005 Sep;19(11):1451-8.

PMID:
16126912
42.

Adult human subventricular, subgranular, and subpial zones contain astrocytes with a specialized intermediate filament cytoskeleton.

Roelofs RF, Fischer DF, Houtman SH, Sluijs JA, Van Haren W, Van Leeuwen FW, Hol EM.

Glia. 2005 Dec;52(4):289-300.

PMID:
16001427
43.

Estrogen receptor-alpha splice variants in the medial mamillary nucleus of Alzheimer's disease patients: identification of a novel MB1 isoform.

Ishunina TA, Swaab DF, Fischer DF.

J Clin Endocrinol Metab. 2005 Jun;90(6):3757-65. Epub 2005 Mar 8.

PMID:
15755860
44.

Molecular misreading: the frequency of dinucleotide deletions in neuronal mRNAs for beta-amyloid precursor protein and ubiquitin B.

Gerez L, de Haan A, Hol EM, Fischer DF, van Leeuwen FW, van Steeg H, Benne R.

Neurobiol Aging. 2005 Feb;26(2):145-55.

PMID:
15582744
45.

Protein quality control in Alzheimer's disease by the ubiquitin proteasome system.

de Vrij FM, Fischer DF, van Leeuwen FW, Hol EM.

Prog Neurobiol. 2004 Dec;74(5):249-70. Review.

PMID:
15582222
46.

Promoter analysis in the human SPRR gene family.

Fischer DF, Backendorf C.

Methods Mol Biol. 2005;289:303-14.

PMID:
15502194
47.

Frame-shifted amyloid precursor protein found in Alzheimer's disease and Down's syndrome increases levels of secreted amyloid beta40.

van Dijk R, Fischer DF, Sluijs JA, Sonnemans MA, Hobo B, Mercken L, Mann DM, Hol EM, van Leeuwen FW.

J Neurochem. 2004 Aug;90(3):712-23.

48.

Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases.

de Pril R, Fischer DF, Maat-Schieman ML, Hobo B, de Vos RA, Brunt ER, Hol EM, Roos RA, van Leeuwen FW.

Hum Mol Genet. 2004 Aug 15;13(16):1803-13. Epub 2004 Jun 15.

PMID:
15198995
49.

Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages.

Wu YH, Feenstra MG, Zhou JN, Liu RY, Toranõ JS, Van Kan HJ, Fischer DF, Ravid R, Swaab DF.

J Clin Endocrinol Metab. 2003 Dec;88(12):5898-906.

PMID:
14671188
50.

Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain.

Fischer DF, De Vos RA, Van Dijk R, De Vrij FM, Proper EA, Sonnemans MA, Verhage MC, Sluijs JA, Hobo B, Zouambia M, Steur EN, Kamphorst W, Hol EM, Van Leeuwen FW.

FASEB J. 2003 Nov;17(14):2014-24.

PMID:
14597671

Supplemental Content

Loading ...
Support Center